Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Assessment of patients with a suspected cardioembolic ischemic stroke. A national consensus statement

    Research output: Contribution to journalReviewResearchpeer-review

  2. Long-term prognosis following hospitalization for acute myocarditis - a matched nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Sex- and age-related differences in the predictive capability of circulating biomarkers: from the MONICA 10 cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Coagulation parameters in the newborn and infant - the Copenhagen Baby Heart and COMPARE studies

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Lipoprotein(a) levels at birth and in early childhood: The COMPARE Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Return to work after COVID-19 infection - A Danish nationwide registry study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVES: In patients with Fabry disease (FD), left ventricular hypertrophy and arrhythmias are frequently observed and cardiac involvement is the leading cause of death. Long-term efficacy of enzyme replacement therapy (ERT) on cardiac involvement is unclear. We assessed and compared long-term progression of cardiac involvement according to ERT and non-ERT.

METHODS: We retrospectively assessed and compared long-term progression of cardiac involvement in adult patients with FD in the nationwide Danish cohort. We followed clinical signs, symptoms and findings by echocardiography, electrocardiography and Holter-monitoring.

RESULTS: We included 66 patients; 47 patients (27 women) received ERT (ERT group) and 19 patients (15 women) did not (non-ERT group). The groups were followed for a median of 8 [0-12] years and 6 [0-13] years, respectively. Comparison between ERT and non-ERT receiving patients by left ventricular mass (echocardiographic assessment) and Sokolow-Lyon voltage- and Cornell product criteria (electrocardiographic assessment) revealed no significant differences. In the ERT group, we observed no change in left ventricular mass but a decrease in Sokolow-Lyon voltage- and Cornell product criteria from baseline to follow-up; 30 mm [15-53] vs. 25 mm [3-44], p < 0.005 and 1710 mm·ms [480-3740] vs. 1520 mm·ms [550-5740], p < .05, respectively. There were no changes within the non-ERT group. During follow-up, cardiac symptoms and use of cardiovascular procedures and -medication increased significantly in the ERT group, whereas no differences were observed within the non-ERT group.

DISCUSSION: We raise concerns regarding the efficacy and benefit of ERT on cardiac involvement in Fabry disease and stress the need for further research.

Original languageEnglish
JournalScandinavian cardiovascular journal : SCJ
Volume51
Issue number4
Pages (from-to)207-216
ISSN1401-7431
DOIs
Publication statusPublished - Aug 2017

    Research areas

  • Journal Article

ID: 51549450